Semaglutide and weight loss – a concern for diabetics and pharmaceuticals
Madam, On 4 June 2021, the FDA approved intravenous Wegovy (semaglutide) for weight-loss management in chronically obese individuals [1]. However, Wegovy, also sold under the name Ozempic, has long been a shortcut for rapid weight loss and gained a reputation as “the worst kept secret in Hollywoo...
I tiakina i:
| Ngā kaituhi matua: | , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Pakistan Medical Association
2024-05-01
|
| Rangatū: | Journal of the Pakistan Medical Association |
| Ngā marau: | |
| Urunga tuihono: | https://jpma.org.pk/index.php/public_html/article/view/10705 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|